retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly's shows promising weight loss results in phase 3 trial retatrutide mechanism triple agonist glp-1

For general maintenance or mild symptoms, once-daily dosing typically suffices and simplifies the protocol

This combination may help support metabolic health, weight balance, and overall energy production

When you're managing conditions like Type 2 Diabetes or PCOS alongside a GLP-1 medication, it's not just about the medication itself

Korosec T, Acimovic J, Seliskar M, Kocjan D, Tacer KF, Rozman D, et al

This is because critical risk factors like smoking, obesity (BMI), and sun exposure were not accounted for in the data

Results build over time: improved sleep quality in weeks two to four, body composition changes by month two, skin and recovery improvements by month three